携带致病或可能致病胚系变异的胰腺导管腺癌患者一级亲属中综合征相关癌症的风险
该病例系列纳入234例携带9个癌症综合征相关基因致病或可能致病胚系变异(PGV)的胰腺导管腺癌先证者及其1670名一级亲属,采用标准化发病比(SIR)评估亲属患胰腺癌及胰腺外癌症的风险。结果显示BRCA1、BRCA2变异者女性亲属卵巢癌风险升高,BRCA2变异者乳腺癌风险升高,林奇综合征错配修复基因变异者子宫内膜癌和结肠癌风险升高,ATM、BRCA2、CDKN2A、PALB2变异者胰腺癌风险升高,CDKN2A变异者黑色素瘤风险升高。作者认为这些基因特异性风险可为临床医生向一级亲属说明遗传级联检测的相关性和重要性提供依据。
要点
- BRCA1变异先证者女性一级亲属卵巢癌SIR 9.49(95%CI 3.06-22.14),BRCA2变异者SIR 3.72(95%CI 1.36-8.11)。
- BRCA2变异先证者一级亲属乳腺癌SIR 2.62(95%CI 1.89-3.54)。
- 林奇综合征错配修复基因变异先证者一级亲属子宫内膜癌SIR 6.53(95%CI 2.81-12.86)、结肠癌SIR 5.83(95%CI 3.70-8.75)。
核心结论
- 在携带9个癌症综合征相关基因PGV的胰腺导管腺癌先证者中,其一级亲属6种癌症风险升高。
- 这些基因特异性胰腺癌及胰腺外癌症风险可为临床医生向一级亲属说明遗传级联检测的相关性和重要性提供依据,以提高检测接受度。
研究设计与样本
- 病例系列,聚焦携带特定癌症综合征相关基因PGV的胰腺导管腺癌先证者的一级亲属。
- 队列来自Mayo Clinic胰腺研究生物样本资源登记库中接受胚系基因检测的临床确认患者。
- 从4562名接受癌症综合征相关基因检测的前瞻性研究登记参与者中选取234例携带PGV的胰腺导管腺癌先证者。
- 人口学及癌症相关家族史通过问卷获取,数据收集时间为2000年10月1日至2021年12月31日。
- 先证者9个癌症综合征相关基因PGV状态来自临床检测,一级亲属癌症由先证者报告,采用标准化发病比(SIR)估计癌症风险。
主要发现
- 研究纳入234例先证者(平均[SD]年龄62.5[10.1]岁;男性124例[53.0%];白人219例[94.4%];非西班牙裔或非拉丁裔225例[98.7%])的1670名一级亲属(平均[SD]年龄58.1[17.8]岁;男性853名[51.1%])。
- BRCA1变异先证者女性一级亲属卵巢癌风险升高(SIR 9.49;95%CI 3.06-22.14),BRCA2变异者亦升高(SIR 3.72;95%CI 1.36-8.11)。
- BRCA2变异先证者一级亲属乳腺癌风险升高(SIR 2.62;95%CI 1.89-3.54)。
- 林奇综合征错配修复基因变异先证者一级亲属子宫内膜癌风险升高(SIR 6.53;95%CI 2.81-12.86),结肠癌风险升高(SIR 5.83;95%CI 3.70-8.75)。
- ATM变异先证者一级亲属胰腺癌风险升高(SIR 4.53;95%CI 2.69-7.16),BRCA2变异者SIR 3.45(95%CI 1.72-6.17),CDKN2A变异者SIR 7.38(95%CI 3.18-14.54),PALB2变异者SIR 5.39(95%CI 1.45-13.79)。
关键数值与推荐
- BRCA1变异先证者女性一级亲属卵巢癌SIR 9.49(95%CI 3.06-22.14)。
- BRCA2变异先证者女性一级亲属卵巢癌SIR 3.72(95%CI 1.36-8.11),一级亲属乳腺癌SIR 2.62(95%CI 1.89-3.54)。
- 林奇综合征错配修复基因变异先证者一级亲属子宫内膜癌SIR 6.53(95%CI 2.81-12.86),结肠癌SIR 5.83(95%CI 3.70-8.75)。
- ATM变异先证者一级亲属胰腺癌SIR 4.53(95%CI 2.69-7.16),BRCA2变异者SIR 3.45(95%CI 1.72-6.17),CDKN2A变异者SIR 7.38(95%CI 3.18-14.54),PALB2变异者SIR 5.39(95%CI 1.45-13.79)。
- CDKN2A变异先证者一级亲属黑色素瘤SIR 7.47(95%CI 3.97-12.77)。
临床怎么用
- 作者认为这些基因特异性胰腺癌及胰腺外癌症风险可为临床医生向一级亲属说明遗传级联检测的相关性和重要性提供依据,目标是提高检测接受度。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Increased cancer risk in first-degree relatives of probands with pancreatic ductal adenocarcinoma (PDAC probands) who carry pathogenic or likely pathogenic germline variants (PGVs) in cancer syndrome-associated genes encourages cascade genetic testing. To date, unbiased risk estimates for the development of cancers on a gene-specific basis have not been assessed. OBJECTIVE: To quantify the risk of development of PDAC and extra-PDAC among first-degree relatives of PDAC probands who carry a PGV in 1 of 9 cancer syndrome-associated genes-ATM, BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2, and CDKN2A. DESIGN, SETTING, AND PARTICIPANTS: This case series focused on first-degree relatives of PDAC probands carrying PGVs in specific cancer syndrome-associated genes. The cohort comprised clinic-ascertained patients enrolled in the Mayo Clinic Biospecimen Resource for Pancreas Research registry with germline genetic testing. In total, 234 PDAC probands carrying PGVs were drawn from the prospective research registry of 4562 participants who had undergone genetic testing of cancer syndrome-associated genes. Demographic and cancer-related family histories were obtained by questionnaire. The data were collected from October 1, 2000, to December 31, 2021. MAIN OUTCOMES AND MEASURES: For the PDAC probands, the genetic test results of the presence of PGVs in 9 cancer syndrome-associated genes were obtained by clinical testing. Cancers (ovary, breast, uterus or endometrial, colon, malignant melanoma, and pancreas) among first-degree relatives were reported by the probands. Standardized incidence ratios (SIRs) were used to estimate cancer risks among first-degree relatives of PDAC probands carrying a PGV. RESULTS: In total, 1670 first-degree relatives (mean [SD] age, 58.1 [17.8] years; 853 male [51.1%]) of 234 PDAC probands (mean [SD] age, 62.5 [10.1] years; 124 male [53.0%]; 219 [94.4%] White; 225 [98.7%] non-Hispanic or non-Latino]) were included in the study. There was a significantly increased risk of ovarian cancer in female first-degree relatives of probands who had variants in BRCA1 (SIR, 9.49; 95% CI, 3.06-22.14) and BRCA2 (SIR, 3.72; 95% CI, 1.36-8.11). Breast cancer risks were higher with BRCA2 variants (SIR, 2.62; 95% CI, 1.89-3.54). The risks of uterine or endometrial cancer (SIR, 6.53; 95% CI, 2.81-12.86) and colon cancer (SIR, 5.83; 95% CI, 3.70-8.75) were increased in first-degree relatives of probands who carried Lynch syndrome mismatch repair variants. Risk of PDAC was also increased for variants in ATM (SIR, 4.53; 95% CI, 2.69-7.16), BRCA2 (SIR, 3.45; 95% CI, 1.72-6.17), CDKN2A (SIR, 7.38; 95% CI, 3.18-14.54), and PALB2 (SIR, 5.39; 95% CI, 1.45-13.79). Melanoma risk was elevated for first-degree relatives of probands with CDKN2A variants (SIR, 7.47; 95% CI, 3.97-12.77). CONCLUSIONS AND RELEVANCE: In this case series, the presence of PGVs in 9 cancer syndrome-associated genes in PDAC probands was found to be associated with increased risk of 6 types of cancers in first-degree relatives. These gene-specific PDAC and extra-PDAC cancer risks may provide justification for clinicians to counsel first-degree relatives about the relevance and importance of genetic cascade testing, with the goal of higher uptake of testing.
引用
- Chen X, Meyer MA, Kemppainen JL, et al. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants. JAMA Oncol. 2023. PMID: 37200008. doi:10.1001/jamaoncol.2023.0806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。